Fulvestrant: 29 Real Stories

Metastatic Breast Cancer Responding to Eribulin After Repeated Liver Progression

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: ER 100%, HER2 negative

Metastatic Site: bone, liver

Eribulin remained ongoing with repeated partial responses documented through 12 cycles and no need for dose reduction.

PubMed CentralRead more →

Metastatic Breast Cancer With Brain, Bone, Lung and Liver Disease Responding During Eribulin Treatment

Patient Info: Anonymized, female, 40s | Stage IV

Biomarkers: Initial tumor: ER 90%, HER2 negative, Ki67 10%. Lung metastasis: ER 90%

Metastatic Site: lung, bone, brain, liver

Eribulin remained ongoing with reduced brain lesions, stable bone disease and continued shrinkage of liver metastases after prior systemic progression.

PubMed CentralRead more →

Metastatic Lobular Breast Cancer With Long-Term Disease Control Across Multiple Therapies

Patient Info: Anonymized, female, 40s | Stage IV

Biomarkers: Initial tumor: ER negative, HER2 negative, Ki67 17%. 2006 recurrence: ER 40%

Metastatic Site: pleura, liver, skin, bone

She was alive on ongoing metronomic vinorelbine with substantial disease stabilization at the most recent follow-up.

PubMed CentralRead more →

Metastatic Breast Cancer With Bone and Liver Progression After Multiple Therapies

Patient Info: Anonymized, female, Under 40 | Stage IV

Biomarkers: Initial tumor: ER 80%, HER2 negative, Ki67 18%. Liver metastasis: ER 75%

Metastatic Site: bone, liver

After massive hepatic progression and liver failure, chemotherapy was stopped and she died on January 31, 2016.

PubMed CentralRead more →

Bilateral Breast Cancers Followed by Metastatic Disease and Long Eribulin Treatment

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: Left primary: ER 90%, HER2 FISH not amplified, Ki67 25%. Right primary: ER 90%

Metastatic Site: lung, pleura, liver, bone

After pelvic bone metastases appeared in 2017, she stopped eribulin, received pelvic radiation and remained on fulvestrant treatment.

PubMed CentralRead more →